Clinical Trials Logo

Clinical Trial Summary

European, multicenter clinical trial with VisioCyt®, an in vitro diagnostic medical device. VisioCyt® is an innovative solution for the early diagnosis of bladder cancer.


Clinical Trial Description

VisioCyt® is based on a patented technology, combining bright-field imaging and artificial intelligence, from a simple urine sample from which the cells are extracted . The main objective of the study is to demonstrate the medical superiority of the VisioCyt® test versus conventional cytology for detecting recurrence of bladder tumors, in patients monitoring non-muscle infiltrating bladder tumors at high and very high risk of progression ;


Study Design


Related Conditions & MeSH terms

  • Non-muscle Invasive Bladder Cancer (NMIBC)

NCT number NCT05176145
Study type Interventional
Source Vitadx
Contact Stéphanie Grojean, PhD
Phone 33 (0)383501921
Email DMIA@fondation-force.fr
Status Recruiting
Phase N/A
Start date April 5, 2022
Completion date May 31, 2025

See also
  Status Clinical Trial Phase
Withdrawn NCT03839472 - Continuous Bladder Irrigation Following Transurethral Resection of Bladder Tumors N/A
Completed NCT03672240 - Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment Phase 1/Phase 2
Recruiting NCT04179162 - Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment Phase 1/Phase 2
Terminated NCT03719300 - Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC Phase 2
Terminated NCT03167151 - Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) Phase 1/Phase 2
Recruiting NCT03148158 - Assessment Of Bladder Tumors Stage And Grade By Outpatient Flexible Cystoscopy Performed By Urology Resident N/A
Terminated NCT06069453 - Hyaluronic Acid Sodium Salt and Hydeal-D in the Management of LUTS After TURBT for NMIBC. N/A
Completed NCT02009332 - Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer Phase 1/Phase 2